Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

This phase I trial studies the side effects and best dose of M5A-IL2 immunocytokine (M5A-ICK) combined with stereotactic body radiation therapy (SBRT) and to see how well they work in treating patients with colorectal cancer or xarcinoembryonic antigen (CEA) positive breast cancer that cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Carcinoembryonic Antigen (CEA) is a protein that is present in most colorectal cancers and in many other cancers, such as breast cancer, as well. SBRT uses special equipm

Trial Details

NCT ID

NCT06130826

Phase

PHASE1

Sponsor

City of Hope Medical Center

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Biopsy
Biospecimen Collection
Bone Scan
Computed Tomography
Immunotherapy
Magnetic Resonance Imaging

Locations (sample)

Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

Patients should have a diagnosis of metastatic colon or rectal or breast cancer that is pathology proven
Patients should have a CEA producing colorectal cancer or breast cancer defined as a baseline CEA or prior documented CEA level exceeding 5 ng/ml o…
Patients should 18 years of age or older
Patients are willing and capable to consent to study and to adhere with all elements of the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →